Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

14.37 +0.36 (+2.57%)
Streaming Delayed Price Updated: 11:01 AM EDT, Jul 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
1 Momentum Stock with Solid Fundamentals and 2 We Avoid
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos... 
Via StockStory
News headline image
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
NeoGenomics (NEO) Stock Trades Up, Here Is Why
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session after the company announced the ... 
Via StockStory
Topics Intellectual Property Lawsuit
NeoGenomics Inc (NASDAQ:NEO) Crushes Estimates on Robust Clinical Growth, Launches Novel MRD Test ↗
Via Chartmill
News headline image
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Looking back on testing & diagnostics services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including NeoGenomics (NASDAQ:NEO) a... 
Via StockStory
News headline image
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
From NeoGenomics, Inc.
Via Business Wire
News headline image
1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofi... 
Via StockStory
News headline image
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
Via StockStory
Topics Economy
News headline image
3 Russell 2000 Stocks We’re Skeptical Of
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
3 Reasons NEO is Risky and 1 Stock to Buy Instead
Over the past six months, NeoGenomics’s shares (currently trading at $9.01) have posted a disappointing 13.4% loss, well below the S&P 500’s 7.1% gain. This ... 
Via StockStory
Topics Bankruptcy Stocks Supply Chain
News headline image
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call
NeoGenomics delivered an 11% year-over-year revenue increase in Q1, exceeding Wall Street’s expectations for the period. Management attributed this performan... 
Via StockStory
Topics Earnings
News headline image
NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 11.1% ye... 
Via StockStory
News headline image
NeoGenomics (NEO) Q1 2026 Earnings Transcript ↗
NeoGenomics (NEO) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
NeoGenomics (NEO) Q1 2025 Earnings Transcript ↗
NeoGenomics (NEO) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 11.1% yea... 
Via StockStory
News headline image
NeoGenomics Reports First Quarter 2026 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics NEO Q2 2025 Earnings Transcript ↗
NeoGenomics NEO Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Retirement
News headline image
NeoGenomics Earnings: What To Look For From NEO
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results this Tuesday after market close. Here’s what investors should know. ... 
Via StockStory
News headline image
Why NeoGenomics (NEO) Stock Is Trading Up Today
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 4.1% in the afternoon session after the company announced that... 
Via StockStory
Topics Artificial Intelligence
News headline image
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
From NeoGenomics, Inc.
Via Business Wire
News headline image
2 Healthcare Stocks Worth Your Attention and 1 We Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl... 
Via StockStory
News headline image
NeoGenomics (NEO) Q4 2024 Earnings Transcript ↗
NeoGenomics (NEO) Q4 2024 Earnings Transcript 
Via The Motley Fool
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.